5 Stocks Investors Are Tracking Now

2. ADMA Biologics Inc. (NASDAQ:ADMA)

ADMA Biologics snapped a five-day losing streak on Friday, soaring 11.58 percent to finish at $9.25 apiece after debunking a short seller report that criticized the company for allegedly issuing misleading information about its growth.

In a statement, ADMA Biologics Inc. (NASDAQ:ADMA) denied Culper Research’s criticism of the demand for Asceniv, saying that it has increased over the past two years based on distributor and customer data.

Additionally, it refuted claims of channel stuffing, saying that there was a “misunderstanding” as distributors must maintain a level of safety stock to ensure that patients prevent from missing treatments.

ADMA Biologics Inc. (NASDAQ:ADMA) also said that its financial statements were clean and that independent auditors reviewed the books with an unqualified opinion.

“ADMA is committed to leading a new age of manufacturing, marketing, and commercializing specialty biologic products for the prevention and treatment of infectious diseases in the immunocompromised and other patients at risk for certain infections, and creating long-term value for its stockholders,” it said.

Despite the clarification, a shareholder law firm remained firm on investigating the short seller report to see if the listed firm may have violated federal securities laws.